Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 26 June, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 506260 | NSE: ANUHPHR

Anuh Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 25, 2025, 4:35 pm

Market Cap 1,049 Cr.
Current Price 209
High / Low 250/148
Stock P/E22.2
Book Value 65.1
Dividend Yield1.20 %
ROCE19.5 %
ROE15.3 %
Face Value 5.00
PEG Ratio2.07

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Anuh Pharma Ltd

Competitors of Anuh Pharma Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
Lactose (India) Ltd 141 Cr. 100 247/84.327.3 41.70.00 %12.9 %9.75 % 10.0
MPS Pharmaa Ltd 5.48 Cr. 2.87 4.33/2.50 0.570.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 41.4 Cr. 55.8 94.9/44.5 8.730.00 %41.5 %14.4 % 10.0
Gujarat Inject (Kerala) Ltd 37.7 Cr. 25.7 29.1/13.137.0 6.830.00 %13.5 %11.0 % 10.0
Industry Average18,565.29 Cr1,158.58103.22194.430.31%16.65%15.19%6.18

All Competitor Stocks of Anuh Pharma Ltd

Quarterly Result

MetricMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
Sales 129116115139157161150172164138166160198
Expenses 115105102126143148132148145127149145179
Operating Profit 14111312141418241911171519
OPM % 11%10%12%9%9%9%12%14%12%8%10%9%9%
Other Income 1122132434311
Interest -0000000000000
Depreciation 3222222222223
Profit before tax 12101312131518252012181317
Tax % 26%24%23%23%25%24%23%24%22%22%17%22%28%
Net Profit 97109101214191510151012
EPS in Rs 1.781.461.981.861.922.342.763.813.071.903.002.062.49

Last Updated: May 31, 2025, 6:59 am

Below is a detailed analysis of the quarterly data for Anuh Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Sales, as of Mar 2025, the value is 198.00 Cr.. The value appears strong and on an upward trend. It has increased from 160.00 Cr. (Dec 2024) to 198.00 Cr., marking an increase of 38.00 Cr..
  • For Expenses, as of Mar 2025, the value is 179.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 145.00 Cr. (Dec 2024) to 179.00 Cr., marking an increase of 34.00 Cr..
  • For Operating Profit, as of Mar 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Dec 2024) to 19.00 Cr., marking an increase of 4.00 Cr..
  • For OPM %, as of Mar 2025, the value is 9.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 9.00%.
  • For Other Income, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 1.00 Cr..
  • For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
  • For Depreciation, as of Mar 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Dec 2024) to 3.00 Cr., marking an increase of 1.00 Cr..
  • For Profit before tax, as of Mar 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Dec 2024) to 17.00 Cr., marking an increase of 4.00 Cr..
  • For Tax %, as of Mar 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Dec 2024) to 28.00%, marking an increase of 6.00%.
  • For Net Profit, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Dec 2024) to 12.00 Cr., marking an increase of 2.00 Cr..
  • For EPS in Rs, as of Mar 2025, the value is 2.49. The value appears strong and on an upward trend. It has increased from 2.06 (Dec 2024) to 2.49, marking an increase of 0.43.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:58 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Sales 266284326206238321307432487527647662
Expenses 242253289183220291284387439476571601
Operating Profit 243138231830234547527661
OPM % 9%11%12%11%8%9%8%10%10%10%12%9%
Other Income 45487541156129
Interest 111101122111
Depreciation 232222715121099
Profit before tax 253238282332193939477861
Tax % 31%31%32%27%29%28%25%26%22%24%23%22%
Net Profit 182226201723142831366047
EPS in Rs 3.514.395.154.003.304.662.865.686.107.2211.999.45
Dividend Payout % 37%27%24%31%42%29%48%26%29%28%21%16%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)22.22%18.18%-23.08%-15.00%35.29%-39.13%100.00%10.71%16.13%66.67%-21.67%
Change in YoY Net Profit Growth (%)0.00%-4.04%-41.26%8.08%50.29%-74.42%139.13%-89.29%5.41%50.54%-88.33%

Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:9%
5 Years:17%
3 Years:11%
TTM:2%
Compounded Profit Growth
10 Years:9%
5 Years:29%
3 Years:18%
TTM:-9%
Stock Price CAGR
10 Years:4%
5 Years:12%
3 Years:32%
1 Year:-10%
Return on Equity
10 Years:15%
5 Years:16%
3 Years:16%
Last Year:15%

Last Updated: Unknown

No data available for the Balance Sheet data table.

Reserves and Borrowings Chart

Cash Flow

MonthMonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +151916262749-1929541337
Cash from Investing Activity +-5-12-5-2023-7752-8-431-20
Cash from Financing Activity +-8-8-9-4-5-722-33-19-12-9-5
Net Cash Flow2-122-13-502-2512

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days821028884100109859690102118107
Inventory Days433327357264649890776657
Days Payable86102797710210589166133117139105
Cash Conversion Cycle393336427068612848624658
Working Capital Days454243517983704468706168
ROCE %26%31%33%35%19%14%19%10%16%18%19%26%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters70.43%70.59%70.59%70.59%70.59%70.59%70.59%69.94%69.91%69.91%69.91%69.91%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.03%0.03%0.02%0.02%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.10%0.00%0.00%0.00%
Public29.56%29.42%29.41%29.40%29.40%29.39%29.40%30.05%29.96%30.05%30.06%30.06%
No. of Shareholders21,12320,74020,45220,47019,96919,42319,06620,51922,23723,49423,91024,048

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) 9.4511.987.226.105.67
Diluted EPS (Rs.) 9.4511.987.226.105.67
Cash EPS (Rs.) 11.1913.709.158.488.68
Book Value[Excl.RevalReserv]/Share (Rs.) 65.0658.1148.1442.6638.04
Book Value[Incl.RevalReserv]/Share (Rs.) 65.0658.1148.1442.6638.04
Dividend / Share (Rs.) 1.502.502.001.751.50
Revenue From Operations / Share (Rs.) 132.01129.11105.2697.1186.20
PBDIT / Share (Rs.) 14.0417.4111.4510.3911.00
PBIT / Share (Rs.) 12.3015.709.528.007.99
PBT / Share (Rs.) 12.1715.639.477.817.69
Net Profit / Share (Rs.) 9.4511.987.226.105.67
PBDIT Margin (%) 10.6313.4810.8710.6912.76
PBIT Margin (%) 9.3112.159.048.239.27
PBT Margin (%) 9.2212.108.998.038.92
Net Profit Margin (%) 7.159.286.856.276.58
Return on Networth / Equity (%) 14.5220.6214.9914.2914.91
Return on Capital Employeed (%) 18.7826.8419.5718.5320.73
Return On Assets (%) 9.3413.478.938.808.54
Total Debt / Equity (X) 0.030.010.000.010.07
Asset Turnover Ratio (%) 1.391.521.401.431.31
Current Ratio (X) 2.112.201.911.981.70
Quick Ratio (X) 1.691.711.461.371.12
Inventory Turnover Ratio (X) 6.186.624.944.364.53
Dividend Payout Ratio (NP) (%) 0.0016.6824.2324.590.00
Dividend Payout Ratio (CP) (%) 0.0014.6019.1117.670.00
Earning Retention Ratio (%) 0.0083.3275.7775.410.00
Cash Earning Retention Ratio (%) 0.0085.4080.8982.330.00
Interest Coverage Ratio (X) 113.62246.74262.7754.1636.88
Interest Coverage Ratio (Post Tax) (X) 77.46170.85166.6632.8020.03
Enterprise Value (Cr.) 736.681223.09392.34417.88446.02
EV / Net Operating Revenue (X) 1.111.890.740.851.03
EV / EBITDA (X) 10.4714.026.848.038.09
MarketCap / Net Operating Revenue (X) 1.131.900.750.881.05
Retention Ratios (%) 0.0083.3175.7675.400.00
Price / BV (X) 2.294.231.652.012.37
Price / Net Operating Revenue (X) 1.131.900.750.881.05
EarningsYield 0.060.040.090.070.06

After reviewing the key financial ratios for Anuh Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
  • For Cash EPS (Rs.), as of Mar 25, the value is 11.19. This value is within the healthy range. It has decreased from 13.70 (Mar 24) to 11.19, marking a decrease of 2.51.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 65.06. It has increased from 58.11 (Mar 24) to 65.06, marking an increase of 6.95.
  • For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.50 (Mar 24) to 1.50, marking a decrease of 1.00.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 132.01. It has increased from 129.11 (Mar 24) to 132.01, marking an increase of 2.90.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 14.04. This value is within the healthy range. It has decreased from 17.41 (Mar 24) to 14.04, marking a decrease of 3.37.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 12.30. This value is within the healthy range. It has decreased from 15.70 (Mar 24) to 12.30, marking a decrease of 3.40.
  • For PBT / Share (Rs.), as of Mar 25, the value is 12.17. This value is within the healthy range. It has decreased from 15.63 (Mar 24) to 12.17, marking a decrease of 3.46.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 9.45. This value is within the healthy range. It has decreased from 11.98 (Mar 24) to 9.45, marking a decrease of 2.53.
  • For PBDIT Margin (%), as of Mar 25, the value is 10.63. This value is within the healthy range. It has decreased from 13.48 (Mar 24) to 10.63, marking a decrease of 2.85.
  • For PBIT Margin (%), as of Mar 25, the value is 9.31. This value is below the healthy minimum of 10. It has decreased from 12.15 (Mar 24) to 9.31, marking a decrease of 2.84.
  • For PBT Margin (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 10. It has decreased from 12.10 (Mar 24) to 9.22, marking a decrease of 2.88.
  • For Net Profit Margin (%), as of Mar 25, the value is 7.15. This value is within the healthy range. It has decreased from 9.28 (Mar 24) to 7.15, marking a decrease of 2.13.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 14.52. This value is below the healthy minimum of 15. It has decreased from 20.62 (Mar 24) to 14.52, marking a decrease of 6.10.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has decreased from 26.84 (Mar 24) to 18.78, marking a decrease of 8.06.
  • For Return On Assets (%), as of Mar 25, the value is 9.34. This value is within the healthy range. It has decreased from 13.47 (Mar 24) to 9.34, marking a decrease of 4.13.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.03. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 1.39. It has decreased from 1.52 (Mar 24) to 1.39, marking a decrease of 0.13.
  • For Current Ratio (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.20 (Mar 24) to 2.11, marking a decrease of 0.09.
  • For Quick Ratio (X), as of Mar 25, the value is 1.69. This value is within the healthy range. It has decreased from 1.71 (Mar 24) to 1.69, marking a decrease of 0.02.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.18. This value is within the healthy range. It has decreased from 6.62 (Mar 24) to 6.18, marking a decrease of 0.44.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 16.68 (Mar 24) to 0.00, marking a decrease of 16.68.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 14.60 (Mar 24) to 0.00, marking a decrease of 14.60.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 83.32 (Mar 24) to 0.00, marking a decrease of 83.32.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 85.40 (Mar 24) to 0.00, marking a decrease of 85.40.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 113.62. This value is within the healthy range. It has decreased from 246.74 (Mar 24) to 113.62, marking a decrease of 133.12.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 77.46. This value is within the healthy range. It has decreased from 170.85 (Mar 24) to 77.46, marking a decrease of 93.39.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 736.68. It has decreased from 1,223.09 (Mar 24) to 736.68, marking a decrease of 486.41.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.11. This value is within the healthy range. It has decreased from 1.89 (Mar 24) to 1.11, marking a decrease of 0.78.
  • For EV / EBITDA (X), as of Mar 25, the value is 10.47. This value is within the healthy range. It has decreased from 14.02 (Mar 24) to 10.47, marking a decrease of 3.55.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
  • For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 83.31 (Mar 24) to 0.00, marking a decrease of 83.31.
  • For Price / BV (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.23 (Mar 24) to 2.29, marking a decrease of 1.94.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.90 (Mar 24) to 1.13, marking a decrease of 0.77.
  • For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Anuh Pharma Ltd as of June 26, 2025 is: 179.02

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 26, 2025, Anuh Pharma Ltd is Overvalued by 14.34% compared to the current share price 209.00

Intrinsic Value of Anuh Pharma Ltd as of June 26, 2025 is: 198.21

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 26, 2025, Anuh Pharma Ltd is Overvalued by 5.16% compared to the current share price 209.00

Last 5 Year EPS CAGR: 10.72%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
    1. Net Profit Margin: 7.15%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 18.78% (Industry Average ROCE: 16.65%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 14.52% (Industry Average ROE: 15.19%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 77.46
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.69
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 22.2 (Industry average Stock P/E: 103.22)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.03
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Anuh Pharma Ltd. is a Public Limited Listed company incorporated on 19/02/1960 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1960PLC011586 and registration number is 011586. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 661.51 Cr. and Equity Capital is Rs. 25.06 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3-A, Shivsagar Estate, Mumbai Maharashtra 400018anuh@sk1932.com
http://www.anuhpharma.com
Management
NamePosition Held
Mr. Arun TodarwalChairman & Non-Exe.Director
Mr. Bipin N ShahVice Chairman
Mr. Ritesh B ShahJoint Managing Director
Mr. Vivek B ShahJoint Managing Director
Mr. Sandeep JoshiIndependent Director
Mr. Harmanbhai PatelIndependent Director
Dr.(Ms.) Mita DixitIndependent Director
Mr. Siddharth J ShahIndependent Director
Mr. Pradeep H ThakurIndependent Director
Mr. Ketan ShahNon Executive Director
Mr. Bharat ShahNon Executive Director
Mr. Samir ShahNon Executive Director
Mr. Gaurav S ShahNon Executive Director
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Anuh Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE